Angle Will Reshape Liquid Diagnostics By Capturing Circulating Tumor Cells
Following a successful fundraise, Angle is poised to further commercialize its proprietary cell-catching technology for cancer diagnosis
You may also be interested in...
The oversubscribed $58m funding round will enable the company to further work on its first-in-class breath biopsy technology, which aims to provide a cheap and convenient screening tool for several diseases.
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
On this episode of Device Week, Medtech Insight’s Marion Webb explains the recent announcement that Johnson & Johnson will split into two separate businesses – one focusing on medical products, and the other focusing on consumer. Barnaby Pickering discusses recent results from the UK’s 100,000 Genome project, and how its analysis partner, Congenica, hopes to deliver personalized medicine through widescale genomic testing.